Christopher A Lamb
YOU?
Author Swipe
View article: Effectiveness and safety of upadacitinib in a real-world cohort of patients with Crohn’s disease in the UK: a multicentre retrospective cohort study
Effectiveness and safety of upadacitinib in a real-world cohort of patients with Crohn’s disease in the UK: a multicentre retrospective cohort study Open
Objective Upadacitinib is the first Janus kinase inhibitor and oral advanced therapy licensed for Crohn’s disease (CD). Following NICE approval in 2023, real-world data on outcomes are limited. The effectiveness and safety of upadacitinib …
View article: Inflammatory bowel disease–dermatology: evaluation of a collaborative, multidisciplinary, patient-centred care model
Inflammatory bowel disease–dermatology: evaluation of a collaborative, multidisciplinary, patient-centred care model Open
Objective Skin disease is common in patients with inflammatory bowel disease (IBD). Patients with severe cutaneous disease often require multidisciplinary management, typically delivered through several separate consultations/discussions l…
View article: Temporal characterization of the gut microbiome and metabolome in preterm infants
Temporal characterization of the gut microbiome and metabolome in preterm infants Open
Preterm infants experience abnormal microbial colonization, which coupled with their vulnerable physiology can increase the risk of disease. Understanding the factors influencing the complex relationship between the temporal development of…
View article: Bacterial Dysbiosis Observed in the Terminal Ileum of Ulcerative Colitis
Bacterial Dysbiosis Observed in the Terminal Ileum of Ulcerative Colitis Open
Lay Summary While ulcerative colitis (UC)–associated inflammation primarily occurs in the colon, subclinical terminal ileum inflammation has been previously observed. Given that colonic microbial dysbiosis is common in UC, we profiled the …
View article: BI25 Inflammatory bowel disease and dermatology: a single-centre cohort review
BI25 Inflammatory bowel disease and dermatology: a single-centre cohort review Open
Skin disease affects up to 15% of patients with inflammatory bowel disease (IBD), most commonly in patients with active disease and a positive family history, and it can precede IBD diagnosis. Inflammatory skin diseases, such as atopic ecz…
View article: Clinical Utility and Cost‐Effectiveness of Pretreatment <i>NUDT15</i> Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the <scp>UK NIHR</scp> Inflammatory Bowel Disease Bioresource
Clinical Utility and Cost‐Effectiveness of Pretreatment <i>NUDT15</i> Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the <span>UK NIHR</span> Inflammatory Bowel Disease Bioresource Open
Background The clinical utility and cost‐effectiveness of pre‐thiopurine NUDT15 pharmacogenetic testing in European and admixed populations are unknown. Aims To report the prevalence, penetrance, expressivity, and pathogenicity of NUDT15 v…
View article: Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients
Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients Open
BACKGROUND AND AIMS: Age is a major prognostic factor for COVID-19 outcomes. The effect of inflammatory bowel disease [IBD] activity on COVID-19 is unclear. We examined the relationship between IBD activity and COVID-19 severity according …
View article: British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease
British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease Open
Patients with inflammatory bowel disease (IBD) remain at increased risk for colorectal cancer and death from colorectal cancer compared with the general population despite improvements in inflammation control with advanced therapies, colon…
View article: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs
The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs Open
CC BY‑NC‑ND 4.0 (open access)
View article: Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs
Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs Open
Background and rationale for guideline development: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition that predominantly affects the spine and sacroiliac joints [1]. It can also involve peripheral joints and entheses, and…
View article: Human milk oligosaccharide metabolism by <i>Clostridium</i> species suppresses inflammation and pathogen growth
Human milk oligosaccharide metabolism by <i>Clostridium</i> species suppresses inflammation and pathogen growth Open
Gut microbiome development is strongly impacted by breastmilk and human milk oligosaccharides (HMOs), with short- and long-term health implications. HMO metabolism is best characterised within bifidobacteria, but the full range of other HM…
View article: Update from 2010 (standard operating procedure): protocol for the 2024 British Society of Gastroenterology Guidelines on colorectal surveillance in inflammatory bowel disease
Update from 2010 (standard operating procedure): protocol for the 2024 British Society of Gastroenterology Guidelines on colorectal surveillance in inflammatory bowel disease Open
Introduction The evolving landscape of inflammatory bowel disease (IBD) necessitates refining colonoscopic surveillance guidelines. This study outlines methodology adopted by the British Society of Gastroenterology (BSG) Guideline Developm…
View article: Integrity Enhancing Protocols: Performance and Recommendations for Nuclear Systems
Integrity Enhancing Protocols: Performance and Recommendations for Nuclear Systems Open
In today’s communication landscape there are multiple technologies and protocols used for communication between end devices. Within security paradigms for these protocols, integrity management is a common goal of system designers. Communic…
View article: Defining predictors of responsiveness to advanced therapies in Crohn’s disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine
Defining predictors of responsiveness to advanced therapies in Crohn’s disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine Open
Introduction Characterised by chronic inflammation of the gastrointestinal tract, inflammatory bowel disease (IBD) symptoms including diarrhoea, abdominal pain and fatigue can significantly impact patient’s quality of life. Therapeutic dev…
View article: Evaluation of emergency hospital admissions for inflammatory bowel disease as a possible marker of quality of care of British IBD inflammatory bowel disease units
Evaluation of emergency hospital admissions for inflammatory bowel disease as a possible marker of quality of care of British IBD inflammatory bowel disease units Open
Background Key performance indicators (KPIs) are required to facilitate quality improvement for inflammatory bowel disease (IBD). Emergency admissions for IBD may represent a possible KPI. Methods IBD emergency admissions for 2018–2019 fro…
View article: Evaluation of YouTube As A Source For Graves' Disease Information: Is High‐Quality Guideline‐Based Information Available?
Evaluation of YouTube As A Source For Graves' Disease Information: Is High‐Quality Guideline‐Based Information Available? Open
Objective To understand the quality of informational Graves' disease (GD) videos on YouTube for treatment decision‐making quality and inclusion of American Thyroid Association (ATA) treatment guidelines. Study Design Cross‐sectional cohort…
View article: P766 No difference in progression of disability 2 years after stopping infliximab or immunosuppressant vs. continuing combination therapy in patients with CD in sustained steroid-free remission: a subanalysis of SPARE
P766 No difference in progression of disability 2 years after stopping infliximab or immunosuppressant vs. continuing combination therapy in patients with CD in sustained steroid-free remission: a subanalysis of SPARE Open
Background In the SPARE trial, the discontinuation of infliximab (IFX) in patients with Crohn’s disease (CD) in sustained remission under combination therapy (IFX and immunosuppressant therapy), was associated with a significantly higher r…
View article: Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource
Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource Open
Background and Aims This study compares the effectiveness of different biologic therapies and sequences in patients with inflammatory bowel disease [IBD] using real-world data from a large cohort with long exposure. Methods Demographic, di…
View article: Conserved γδ T cell selection by BTNL proteins limits progression of human inflammatory bowel disease
Conserved γδ T cell selection by BTNL proteins limits progression of human inflammatory bowel disease Open
Murine intraepithelial γδ T cells include distinct tissue-protective cells selected by epithelial butyrophilin-like (BTNL) heteromers. To determine whether this biology is conserved in humans, we characterized the colonic γδ T cell compart…
View article: Opioid use and associated factors in 1676 patients with inflammatory bowel disease: a multicentre quality improvement project
Opioid use and associated factors in 1676 patients with inflammatory bowel disease: a multicentre quality improvement project Open
Objective Despite its association with poorer outcomes, opioid use in inflammatory bowel disease (IBD) is not well characterised in the UK. We aimed to examine the extent of opioid use, the associated factors and the use of mitigation tech…
View article: Establishing key performance indicators for inflammatory bowel disease in the UK
Establishing key performance indicators for inflammatory bowel disease in the UK Open
Background and aims Healthcare quality improvement (QI) is the systematic process to continuously improve the quality of care and outcomes for patients. The landmark Inflammatory Bowel Disease (IBD) UK National Audits provided a means to m…
View article: Considerations for peripheral blood transport and storage during large-scale multicentre metabolome research
Considerations for peripheral blood transport and storage during large-scale multicentre metabolome research Open
We read with interest the multiomic studies by Kong et al and Chen et al examining gut microbiome-metabolome interactions and potential diagnostic and classification biomarkers in colorectal cancer.1 2 Large-scale, multicentre, multisample…
View article: OP33 Results of a randomised controlled trial to evaluate Interleukin 1 blockade with anakinra in patients with acute severe ulcerative colitis (IASO)
OP33 Results of a randomised controlled trial to evaluate Interleukin 1 blockade with anakinra in patients with acute severe ulcerative colitis (IASO) Open
Background Acute severe ulcerative colitis (ASUC) is a severe manifestation of ulcerative colitis (UC) that requires hospitalisation. Despite significant advances in therapeutic options for UC and in the medical management of steroid-refra…
View article: OP24 Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with Inflammatory Bowel Disease after three doses of COVID-19 vaccine: a prospective multicentre cohort study
OP24 Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with Inflammatory Bowel Disease after three doses of COVID-19 vaccine: a prospective multicentre cohort study Open
Background Anti-tumour necrosis factor drugs such as infliximab are associated with attenuated antibody responses after COVID-19 vaccination. It is unknown how infliximab impacts vaccine-induced serological responses against highly transmi…
View article: Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations
Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations Open
Checkpoint inhibitors (CPIs) are monoclonal antibodies which, by disrupting interactions of immune checkpoint molecules with their ligands, block regulatory immune signals otherwise exploited by cancers. Despite revolutionary clinical bene…
View article: Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study Open
Royal Devon University Healthcare NHS Foundation Trust; Hull University Teaching Hospital NHS Trust; NIHR Imperial Biomedical Research Centre; Crohn's and Colitis UK; Guts UK; National Core Studies Immunity Programme, UK Research and Innov…